Cenicriviroc: Additional Phase IIb data

Additional data from the double-blind, double-dummy, U.S. and Puerto Rican Phase IIb Study 202 trial in 143 treatment-naïve patients with CCR-5-tropic HIV-1 infection showed that 76% of patients receiving once-daily 100 mg oral cenicriviroc plus Truvada emtricitabine/tenofovir and 73% of patients

Read the full 411 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE